A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

The real-world intracranial overall response rate (rwICORR) at Month 3,The real-world intracranial overall response rate (rwICORR) at Month 6,The real-world intracranial overall response rate (rwICORR) at Month 12,The real-world intracranial clinical benefit rate (rwICBR) at Month 3,The real-world intracranial clinical benefit rate (rwICBR) at Month 6,The real-world intracranial clinical benefit rate (rwICBR) at Month 12,The real-world intracranial time to progression (rwICTTP),The real-world systemic overall response rate (rwORR) at Month 3,The real-world systemic overall response rate (rwORR) at Month 6.,The real-world systemic overall response rate (rwORR) at Month 12.,The real-world progression-free survival (rwPFS) during 12 months from index date,The real-world overall survival (rwOS) during 12 months from index date,The real-world overall survival (rwOS) during 24 months from index date

The purpose of this study is to learn about dacomitinib for the possible treatment of lung
 cancer which has spread to other parts of the body.
 
 This study is seeking participants who:
 
 - have lung cancer that has reached at least the brain.
 
 - have a type of gene called epidermoid growth factor receptor. A gene is a part of your
 DNA that has instructions for making things your body needs to work.
 
 - have not received any treatment before.
 
 All participants in this study will receive dacomitnib 1 time a day. Dacomitinib is a tablet
 that is taken by mouth at home. They can continue to take dacomitnib until their cancer is no
 longer responding. The study will look at the experiences of people receiving the study
 medicine. This will help to see if the study medicine is safe and effective.